HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Laryngeal amyloidosis — Clinical Guidelines

Overview

Localized laryngeal amyloidosis is a benign condition characterized by the deposition of AL amyloid fibrils derived from immunoglobulin light chains in the larynx, distinct from systemic amyloidosis where amyloid deposits occur throughout the body. It primarily affects adults, often presenting with dysphonia, dyspnea, or both, due to involvement of critical laryngeal structures such as the vocal cords and subglottis. Given its rarity and potential for significant functional impairment, accurate diagnosis and timely intervention are crucial for preserving voice quality, swallowing function, and respiratory comfort. Understanding this condition is vital for otolaryngologists and clinicians managing patients with persistent laryngeal symptoms to ensure appropriate management and avoid misdiagnosis. 1 3 4

Pathophysiology

Localized laryngeal amyloidosis arises from the accumulation of extracellular AL amyloid fibrils, typically composed of immunoglobulin light chains produced by clonal plasma cells in the vicinity of the larynx. These fibrils are insoluble and progressively accumulate in laryngeal tissues, leading to structural changes and functional impairment depending on the affected regions. The exact triggers for clonal plasma cell activation and light chain misfolding remain unclear, though some cases may be associated with underlying systemic amyloidosis. Over time, these deposits can cause mechanical obstruction, inflammation, and tissue stiffness, manifesting clinically as hoarseness, dysphagia, or respiratory distress. The pathogenesis underscores the importance of early detection and intervention to prevent irreversible laryngeal damage. 1 17 18

Epidemiology

Localized laryngeal amyloidosis is exceedingly rare, with incidence figures not extensively documented in large population studies. Most reported cases involve adults, with a slight female predominance noted in some series. Geographic distribution does not appear to show significant variations, suggesting no specific regional risk factors. The condition can occur at any age but is predominantly diagnosed in middle-aged and older adults. Limited longitudinal data suggest no clear temporal trends, but the rarity of the condition makes robust epidemiological analysis challenging. 1 7 10

Clinical Presentation

Patients typically present with chronic symptoms such as persistent hoarseness, which is often the earliest and most common complaint. Dyspnea, particularly in cases involving the subglottis, and dysphagia may also occur depending on the extent and location of amyloid deposits. Less commonly, patients might report throat pain or a sensation of a foreign body in the throat. Red-flag features include rapid progression of symptoms, systemic signs suggestive of systemic amyloidosis (e.g., weight loss, fatigue), and recurrent laryngeal obstruction. Early recognition is critical to prevent functional deterioration and to rule out systemic involvement. 1 10 18

Diagnosis

The diagnosis of localized laryngeal amyloidosis involves a high index of suspicion based on clinical presentation and characteristic findings on direct laryngoscopy. Key diagnostic steps include:

Clinical Evaluation: Detailed history focusing on persistent dysphonia, dyspnea, and dysphagia.

Direct Laryngoscopy: Essential for visualizing characteristic amyloid lesions, typically firm, non-ulcerated, and yellowish or white in color.

Biopsy: Definitive diagnosis requires histopathological examination showing amyloid deposits with Congo red staining and apple-green birefringence under polarized light microscopy. Immunohistochemical analysis often confirms the AL type by identifying immunoglobulin light chains.

Exclusion of Systemic Amyloidosis: Comprehensive evaluation to rule out systemic amyloidosis through blood tests (e.g., serum protein electrophoresis, free light chain assay), imaging (e.g., PET scan), and possibly bone marrow biopsy.

Differential Diagnosis:

Laryngeal Cancer: Biopsy differentiation is crucial; amyloid deposits lack malignant features.

Laryngeal Papillomatosis: Characterized by wart-like growths, often in pediatric patients.

Laryngeal Granuloma: Typically presents with a single, well-defined mass, often post-intubation.

Amyloidosis (Systemic): Systemic involvement requires broader organ assessment and specific biomarker testing. 1 3 13 16

Management

Surgical Management

First-line Treatment:

Complete Excision: Preferred approach, especially for lesions amenable to precise surgical techniques.

- Techniques: Cold steel excision for delicate areas like vocal cords; CO2 laser or microdebrider for larger or more accessible lesions. - Contraindications: High risk of scarring, dysphonia, or dysphagia if complete excision is technically challenging.

Second-line Treatment:

Debulking: When complete excision poses significant risks, partial removal to alleviate symptoms.

Follow-up Monitoring: Annual laryngoscopy and clinical evaluation if complete excision is not feasible.

Refractory Cases:

Referral to Specialist: Consider referral to centers with expertise in complex laryngeal surgeries or systemic amyloidosis management.

Consider Irradiation: Rarely indicated, typically in cases where surgery is contraindicated or has failed.

Monitoring and Postoperative Care:

Voice Rehabilitation: Speech therapy may be necessary post-surgery to optimize vocal function.

Regular Follow-up: Every 6-12 months to monitor for recurrence and systemic involvement. 1 3 5 8

Complications

Recurrent Symptoms: Persistent hoarseness, dyspnea, or dysphagia may indicate incomplete resection or recurrence.

Scarring and Dysphonia: Potential complications of aggressive surgical interventions.

Systemic Amyloidosis: Development of systemic symptoms necessitates broader evaluation and management.

Referral Triggers: Rapid symptom progression, suspicion of systemic involvement, or failure to respond to initial treatment should prompt referral to a specialist. 4 14

Prognosis & Follow-up

The prognosis for localized laryngeal amyloidosis is generally favorable with appropriate surgical intervention, often leading to symptom resolution and long disease-free intervals. Key prognostic indicators include:

Complete Resection: Associated with lower recurrence rates.

Subglottic Involvement: Identified as an independent risk factor for recurrence.

Systemic Evaluation: Absence of systemic amyloidosis markers is favorable.

Recommended Follow-up:

Initial Postoperative: Within 1-2 weeks for wound healing assessment.

Short-term (3-6 months): To ensure symptom resolution and voice recovery.

Long-term (Annually): To monitor for recurrence and systemic complications. 4 1 7

Special Populations

Pediatric Patients: Rare but possible; diagnosis requires high suspicion given atypical presentations. 2

Elderly Patients: More common due to increased prevalence of age-related plasma cell dyscrasias; careful assessment for systemic involvement is crucial.

Comorbidities: Presence of other systemic diseases may complicate diagnosis and management, necessitating thorough systemic evaluation. 1 10

Key Recommendations

Suspect Localized Laryngeal Amyloidosis in Patients with Persistent Dysphonia or Dyspnea, especially with characteristic laryngeal lesions (Evidence: Moderate) 1 3

Perform Direct Laryngoscopy and Biopsy for Definitive Diagnosis, confirming amyloid deposits via histopathological examination (Evidence: Strong) 1 16

Exclude Systemic Amyloidosis Through Comprehensive Laboratory and Imaging Studies before concluding localized disease (Evidence: Moderate) 3 4

Prioritize Complete Excision of Amyloid Lesions when feasible to minimize recurrence risk (Evidence: Moderate) 1 3

Implement Regular Follow-Up (Annually) to monitor for recurrence and systemic involvement (Evidence: Moderate) 1 7

Refer to Specialists for Complex Cases or Recurrent Disease, especially if systemic amyloidosis is suspected (Evidence: Expert opinion) 14

Consider Voice Rehabilitation Post-Surgery to optimize vocal function (Evidence: Moderate) 1

Be Vigilant for Subglottic Involvement as a Risk Factor for Recurrence and tailor management accordingly (Evidence: Moderate) 4

Evaluate Pediatric Patients with High Suspicion due to atypical presentations and rarity (Evidence: Expert opinion) 2

Assess for Comorbidities That May Influence Diagnosis and Management, ensuring comprehensive systemic evaluation (Evidence: Moderate) 1 10

References

1 Hazenberg AJ, Hazenberg BP, Dikkers FG. Long-term follow-up after surgery in localized laryngeal amyloidosis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2016. link 2 Pardo Jadue J, Ramírez Pelayo C, Lanas Volz A. Localized laryngeal amyloidosis: an unusual diagnosis in pediatric patients. Case report. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2025. link 3 Silver JA, Lahijanian Z, Kay-Rivest E, Marquez JC, Young J, Chagnon F et al.. Laryngeal Amyloidosis: What is the Role of Imaging?. Journal of voice : official journal of the Voice Foundation 2025. link 4 Shi Y, Xie M, Zhang QQ, Guo RX, Qiang Y, Yang HN et al.. The subglottic involvement is an independent risk factor for recurrence of laryngeal amyloidosis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2023. link 5 Galluzzi F, Garavello W. Surgical treatment of laryngeal amyloidosis: a systematic review. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2023. link 6 Mao M, Liang N, Ren R, Zhao Y, Ma D, Liu H. A Nomogram Model for Predicting the Postoperative Recurrence of Localized Laryngeal Amyloidosis. The Annals of otology, rhinology, and laryngology 2023. link 7 Harris G, Lachmann H, Hawkins P, Sandhu G. One Hundred Cases of Localized Laryngeal Amyloidosis - Evidence for Future Management. The Laryngoscope 2021. link 8 Wu X, Zhang J, Wei C. Risk factors for recurrence of laryngeal amyloidosis treated by microforceps and CO. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020. link 9 Burns H, Phillips N. Laryngeal amyloidosis. Current opinion in otolaryngology & head and neck surgery 2019. link 10 Phillips NM, Matthews E, Altmann C, Agnew J, Burns H. Laryngeal amyloidosis: diagnosis, pathophysiology and management. The Journal of laryngology and otology 2017. link 11 Bozkus F, Ulas T, Lynen I, Ozardali I, Sans I. Primary localised laryngeal amyloidosis. JPMA. The Journal of the Pakistan Medical Association 2013. link 12 Oğuz H, Safak MA, Demirci M, Arslan N. Familial primary localized laryngeal amyloidosis in two sisters. Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat 2007. link 13 Siddachari RC, Chaukar DA, Pramesh CS, Naresh KN, de Souza CE, Dcruz AK. Laryngeal amyloidosis. The Journal of otolaryngology 2005. link 14 Ma L, Bandarchi B, Sasaki C, Levine S, Choi Y. Primary localized laryngeal amyloidosis: report of 3 cases with long-term follow-up and review of the literature. Archives of pathology & laboratory medicine 2005. link 15 Hellquist HB. Apoptosis in epithelial hyperplastic laryngeal lesions. Acta oto-laryngologica. Supplementum 1997. link 16 Lewis JE, Olsen KD, Kurtin PJ, Kyle RA. Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1992. link 17 Westermark P, Sletten K, Pitkänen P, Natvig JB, Lindholm CE. Localized laryngeal amyloidosis: partial characterization of an amyloid fibril protein AL. Molecular immunology 1982. link90210-3) 18 Barnes EL, Zafar T. Laryngeal amyloidosis: clinicopathologic study of seven cases. The Annals of otology, rhinology, and laryngology 1977. link

Laryngeal amyloidosis